Vibrant Therapeutics secured multi-million dollar Series A financing to advance its intelligent macromolecule drug R&D and global clinical trials.

Target Company Overview

Vibrant Therapeutics (Guangzhou) Co., Ltd. specializes in the research and development of next-generation intelligent macromolecule drugs. Founded in 2019 by Dr. Luquan Wang, a prominent figure in drug development and the founder of GenScript, the company boasts a leadership team with an average of over 20 years of experience in macromolecule drug research. The team has held significant roles at respected pharmaceutical and biotechnology firms such as Schering-Plough, Merck, and GenScript. Vibrant’s primary focus lies within the realm of tumour immunotherapy, where it develops innovative drug candidates designed to target solid tumours. Utilizing a unique